AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31236782
Drug: Sequential compression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential compression devices (SCDs) applied to the arm harboring the PICC
Trial: 31236782
Drug: Sequential compression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential compression devices (SCDs) applied to the arm harboring the PICC (after accounting for crossovers)
Trial: 30702019
Drug: Deutetrabenazine dosed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deutetrabenazine dosed 24-48 mg/day
Trial: 28489298
Drug: ALA‐PDT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA‐PDT plus cetirizine 10 mg (n=10)
Trial: 22907731
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) treatment in blacks
Trial: 18489017
Drug: therapist-delivered CRA
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: therapist-delivered CRA treatment with vouchers
Trial: 18489017
Drug: computer-assisted CRA
RxNorm normalized name: CRA-028129
DrugBank: CRA-028129 (DB05951)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: computer-assisted CRA treatment with vouchers
Trial: 11865833
Drug: Pentoxifylline (PXF)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PXF) 1800 mg daily
Trial: 9741018
Drug: Intravenous corticotrophin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous corticotrophin (ACTH) 120 U/day
Trial: 9741018
Drug: Hydrocortisone 300
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone 300 mg/day
Trial: 8275731
Drug: N-acetylcysteine (NAC),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC), 40 mg/kg/d, intravenously for 3 days
Trial: 2500462
Drug: Flunitrazepam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (2 mg intravenously)
Trial: 29957136
Drug: Spatone supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spatone supplement
Trial: 21639596
Drug: Alcohol (0.82
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.82 g/kg males; 0.74 g/kg females)
Trial: 19528265
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of ceftazidime (200 mg/kg of body weight/day)
Trial: 19528265
Drug: Short infusions
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short infusions of ceftazidime (200 mg/kg of body weight/day)
Trial: 11349744
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of ceftazidime
Trial: 19528265
Drug: Short infusions
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short infusions of ceftazidime
Trial: 3182964
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose calcitriol (≤ 0.50 micrograms/day)
Trial: 19040806
Drug: Papacárie gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papacárie gel (chemomechanical caries removal agent)
Trial: 21175439
Drug: oseltamivir 75
RxNorm normalized name: oseltamivir 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oseltamivir 75 mg twice daily for 4.5 days
Trial: 11304904
Drug: warfarin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: warfarin alone
Trial: 21175439
Drug: oseltamivir +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oseltamivir + warfarin
Trial: 18723329
Drug: Antibiotic lock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic lock therapy
Trial: 18723329
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous administration of antibiotics
Trial: 14585939
Drug: ximelagatran (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ximelagatran (24 mg, taken twice daily for 18 months)
Trial: 10972907
Drug: G‐CSF (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (300 microg filgrastim) given three times weekly for 12 weeks
Trial: 9526580
Drug: Filgrastim (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgrastim (5 mg/kg) following PBPC infusion
Trial: 8317948
Drug: 2‐deoxyglucose (2DG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2‐deoxyglucose (2DG) 50 mg/kg
Trial: 31692226
Drug: Exenatide (EXE)
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide (EXE) once weekly + dapagliflozin (DAPA) once daily
Trial: 31692226
Drug: Exenatide (EXE)
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide (EXE) once weekly + placebo (PLB)
Trial: 26535593
Drug: Febuxostat 40-80
RxNorm normalized name: febuxostat 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat 40-80 mg daily
Trial: 26535593
Drug: Allopurinol 100-300
RxNorm normalized name: allopurinol 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 100-300 mg daily
Trial: 18206734
Drug: 1997 ADA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1997 ADA IFG definition (fasting plasma glucose 110 to 125 mg/dl)
Trial: 18206734
Drug: 2003 ADA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2003 ADA IFG definition (fasting plasma glucose 100 to 125 mg/dl)
Trial: 7986706
Drug: Control (ICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (ICE chemotherapy without IL‐3)
Trial: 2525397
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy with medroxyprogesterone acetate at high dosage (HD‐MPA; 500 mg IM per day times 28 or 500 mg i.m. 5 days a week for 5 weeks then 500 mg i.m. twice weekly for the 5 following months
Trial: 4883651
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive with low oestrogen/progestogen content
Trial: 4883651
Drug: Identical dummy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical dummy tablets (control)
Trial: 19556318
Drug: Trabectedin 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin 1.5 mg/m2 24 h (arm A)
Trial: 19556318
Drug: Trabectedin 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin 1.3 mg/m2 3 h (arm B)
Trial: 14718678
Drug: Levodopa combined
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa combined with COMT inhibitor entacapone
Trial: 9885092
Drug: Psychological intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychological intervention consisting of 35 weekly, 2 h sessions of supportive plus cognitive behavioral therapy; n = 30
Trial: 30864473
Drug: Paracetamol compliance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol compliance
Trial: 30864473
Drug: Oxycodone immediate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone immediate release (IR) compliance
Trial: 30864473
Drug: Oxycodone IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone IR quantity compliance
Trial: 17381566
Drug: Levobupivacaine 0.5%
RxNorm normalized name: levobupivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.5% (20 ml)
Trial: 12363117
Drug: Fluvoxamine (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (median dose 150 mg, range 50-300 mg)
Trial: 1103574
Drug: Maprotiline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maprotiline and Amitriptyline (both drugs)
Trial: 30811280
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg (NIVO3+IPI1)
Trial: 30811280
Drug: Nivolumab 1
RxNorm normalized name: nivolumab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg (NIVO1+IPI3)
Trial: 27007714
Drug: Engage in
RxNorm normalized name: Bispecific t-cell engager antibody regn4018
DrugBank: Ubamatamab (DB18875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engage in Education‐London (EiE‐L) intervention, delivered over 12 weeks
Trial: 23695652
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy (OMT) including lifestyle intervention and intensive secondary prevention with proven pharmacotherapies
Trial: 14583439
Drug: Protocol 2
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol 2 (6 h of mild hyperglycemia, approximately 7 mmol/l)
Trial: 14583439
Drug: Protocol 1
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol 1 (glucose varied to mimic a postprandial pattern, peak glucose approximately 11.1 mmol/l)
Trial: 9415507
Drug: No analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No analgesic treatment
Trial: 8395380
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMW heparin) administered subcutaneously once daily
Trial: 3706840
Drug: Spinal anaesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anaesthesia with 3 ml 0.5% bupivacaine in isobaric solution
Trial: 21919060
Drug: Sertraline responders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline responders
Trial: 21919060
Drug: Sertraline non-responders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline non-responders
Trial: 20206786
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone ER (3, 9, and 15 mg/d; 6, 9, and 12 mg/d; 6 and 12 mg/d)
Trial: 16266859
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg n-3 PUFA + 700 mg canola oil
Trial: 16266859
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g canola oil (control)
Trial: 12019663
Drug: Fluoxetine (20-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20-60 mg daily)
Trial: 10466664
Drug: Community-wide oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-wide oral azithromycin treatment (three doses with intervals of 1 week)
Trial: 10466664
Drug: 1% topical
RxNorm normalized name: SSD 1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% topical tetracycline (once daily for 6 weeks)
Trial: 3918426
Drug: Intracoronary thrombolytic
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary thrombolytic therapy with streptokinase (STK)
Trial: 3918426
Drug: Corticosteroids and
RxNorm normalized name: Corticosteroids and mydriatics in combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids and intracoronary and intravenous nitroglycerin (NTG group)
Trial: 31554937
Drug: Esaxerenone monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esaxerenone monotherapy
Trial: 31554937
Drug: Esaxerenone with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esaxerenone with RAS inhibitor
Trial: 25533646
Drug: Mesalazine, 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine, 800 mg, three times daily for 12 weeks
Trial: 25533646
Drug: Placebo, three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, three times daily for 12 weeks
Trial: 23566712
Drug: Balanced electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced electrolyte solution
Trial: 19114201
Drug: Single-dose cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose cefazolin (2 g)
Trial: 19114201
Drug: 24-hour treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour treatment of cefazolin (2-g initial dose, followed by 1 g every 8 hours)
Trial: 12828083
Drug: Twice-a-day interferon-beta
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-a-day interferon-beta (3 MU) for 3 weeks followed by once-a-day interferon-beta (6 MU) for 5 weeks (group A)
Trial: 12828083
Drug: Twice-a-day interferon-beta
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-a-day interferon-beta (group A)
Trial: 11074884
Drug: 131I-lipiodol (1110-MBq
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 131I-lipiodol (1110-MBq dose) administered into the hepatic artery
Trial: 79319
Drug: 2-month initial
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-month initial intensive phase of streptomycin, isoniazid, rifampin, and pyrazinamide followed by daily thiacetazone and isoniazid
Trial: 79319
Drug: 1-month initial
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1-month initial intensive phase of streptomycin, isoniazid, rifampin, and pyrazinamide followed by twice-weekly administration of streptomycin, isoniazid, and pyrazinamide
Trial: 79319
Drug: Total duration
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total duration of chemotherapy increased from 6 months to 8 months
Trial: 29097166
Drug: Active product
RxNorm normalized name: collagen,activated Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active product (125 mL once-a-day drink containing Fortasyn Connect)
Trial: 25399241
Drug: Weekly acupuncture
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly acupuncture treatment (n = 118)
Trial: 25399241
Drug: Oral tolterodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tolterodine tartrate 2 mg twice daily (n = 122)
Trial: 21680210
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine 0.25 mg/kg body weight
Trial: 16935098
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (2 g as an intravenous bolus before sternotomy)
Trial: 10889591
Drug: Subcutaneous IL‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous IL‐2 (7.5 mIU twice per day in 5-day courses every 8 weeks) + ART
Trial: 10889591
Drug: Subcutaneous IL‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous IL‐2 + ART
Trial: 9096917
Drug: Fluvastatin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (30 mg/day) added to probucol treatment for 12 weeks
Trial: 9096917
Drug: Fluvastatin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (30 mg/day)
Trial: 9690694
Drug: Intravenous mCPP
RxNorm normalized name: MCPP
DrugBank: m-Chlorophenylpiperazine (DB12110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous mCPP (0.1 mg/kg)
Trial: 8420593
Drug: Intravenous mCPP
RxNorm normalized name: MCPP
DrugBank: m-Chlorophenylpiperazine (DB12110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous mCPP
Trial: 8420593
Drug: Oral mCPP
RxNorm normalized name: MCPP
DrugBank: m-Chlorophenylpiperazine (DB12110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mCPP
Trial: 8420593
Drug: Metergoline pretreatment
RxNorm normalized name: Metergoline
DrugBank: Metergoline (DB13520)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metergoline pretreatment prior to intravenous mCPP
Trial: 2868029
Drug: dipyridamole (Persantine)
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dipyridamole (Persantine) plus aspirin
Trial: 19891665
Drug: CB-01-05 MMX
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB-01-05 MMX 210 mg tablets
Trial: 16427529
Drug: Propofol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.5 mg/kg bolus over 10 minutes, followed by continuous infusion at 1 mg/kg per hour)
Trial: 12873935
Drug: IV lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lidocaine 0.2 mg/kg followed by propofol infusion
Trial: 12873935
Drug: IV normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV normal saline (placebo) followed by propofol 1%/lidocaine 1% mixture infusion
Trial: 8915224
Drug: Low-dose ANP
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ANP (3 pmol/kg/min)
Trial: 8915224
Drug: Low-dose BNP
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose BNP (3 pmol/kg/min)
Trial: 8915224
Drug: High-dose ANP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ANP (10 pmol/kg/min)
Trial: 8915224
Drug: High-dose BNP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose BNP (10 pmol/kg/min)
Trial: 8915224
Drug: Low-dose ANP
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ANP
Trial: 8915224
Drug: High-dose ANP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ANP
Trial: 8915224
Drug: Low-dose BNP
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose BNP
Trial: 8915224
Drug: High-dose BNP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose BNP
Trial: 1860210
Drug: Biphasic waveform
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biphasic waveform defibrillation (RV-LV epicardial patches)
Trial: 6341017
Drug: Maximized insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maximized insulin treatment
Trial: 26915009
Drug: Autologous Protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous Protein Solution (APS)
Trial: 26792933
Drug: Vardenafil 10
RxNorm normalized name: vardenafil 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil 10 mg twice a day for 24 weeks
Trial: 24557078
Drug: Baseline bilirubin
RxNorm normalized name: bilirubin preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline bilirubin level of 0.5 mg/dl or higher with hemoglobin concentrations of 14 g/dl or higher
Trial: 24557078
Drug: Baseline bilirubin
RxNorm normalized name: bilirubin preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline bilirubin level <0.5 mg/dl with hemoglobin concentration <14 g/dl
Trial: 22897752
Drug: Carboplatin/paclitaxel (AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin/paclitaxel (AUC 5/6; 200 mg/m(2))
Trial: 11457553
Drug: DTPa-HBV/Hib vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa-HBV/Hib vaccine administered as a single injection (Group 1)
Trial: 11457553
Drug: DTPa-HBV and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa-HBV and Hib vaccines administered simultaneously at separate sites (Group 2)
Trial: 9734938
Drug: TNF alpha
RxNorm normalized name: TNF alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF alpha MAb (7.5 mg/kg)
Trial: 3289293
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (twice daily injections)
Trial: 29956440
Drug: Topical EGF
RxNorm normalized name: ABX-EGF
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical EGF ointment
Trial: 26583667
Drug: LCT-EOS >3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCT-EOS >3 mmol/L
Trial: 19674280
Drug: Human intravenous
RxNorm normalized name: Glassia, human intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human intravenous immunoglobulin (hIVIG) 0.5 g/kg
Trial: 10931101
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose short synacthen test (HDT, 250 microgram)
Trial: 10931101
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose short synacthen test (LDT, 1 microgram)
Trial: 8147961
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A (1500 mg RE/d)
Trial: 3092269
Drug: Ro 15‐1788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15‐1788 30 mg
Trial: 3092269
Drug: Ro 15‐1788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15‐1788 100 mg
Trial: 31718953
Drug: Prasugrel 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 3.75 mg once daily
Trial: 30340503
Drug: Aerobic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerobic and resistance exercise intervention (moderate-vigorous, 65-85% heart rate maximum, thrice weekly for 16 weeks)
Trial: 24758077
Drug: Sulfasalazine Enteric-coated
RxNorm normalized name: sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfasalazine Enteric-coated Tablet (SECT), 0.5 g three times daily for 3 months (Control)